Holen Sie sich die Stockscreener-App
6.86
104.78%
3.51
Vorhandelsmarkt:
6.85
-0.01
-0.15%
Schlusskurs vom Vortag:
$3.35
Offen:
$6.88
24-Stunden-Volumen:
24.71M
Relative Volume:
15.00
Marktkapitalisierung:
$552.48M
Einnahmen:
$414.29M
Nettoeinkommen (Verlust:
$-99.81M
KGV:
-5.1393
EPS:
-1.3348
Netto-Cashflow:
$-28.65M
1W Leistung:
+100.58%
1M Leistung:
+89.50%
6M Leistung:
+101.76%
1J Leistung:
-54.24%
1-Tages-Spanne:
$6.84
$6.92
1-Wochen-Bereich:
$3.33
$6.92
52-Wochen-Spanne:
$3.08
$15.36
Accolade Inc Stock (ACCD) Company Profile
Firmenname
Accolade Inc
Sektor
Branche
Telefon
610-834-2989
Adresse
660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING
Vergleichen Sie ACCD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACCD
Accolade Inc
|
6.86 | 552.48M | 414.29M | -99.81M | -28.65M | -1.3348 |
|
VEEV
Veeva Systems Inc
|
217.30 | 35.28B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
68.96 | 11.91B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
55.00 | 10.27B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
99.74 | 8.64B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.51 | 6.45B | 906.14M | -52.62M | 89.62M | -0.3621 |
Accolade Inc Stock (ACCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Bestätigt | Needham | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-17 | Fortgesetzt | DA Davidson | Neutral |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-24 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-04-12 | Eingeleitet | Stephens | Overweight |
| 2023-03-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-02-09 | Herabstufung | Jefferies | Buy → Hold |
| 2023-02-02 | Eingeleitet | Raymond James | Outperform |
| 2022-09-08 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-09-07 | Eingeleitet | Truist | Buy |
| 2022-08-12 | Eingeleitet | DA Davidson | Buy |
| 2022-05-02 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-04-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-29 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Underweight |
| 2022-04-07 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Berenberg | Buy |
| 2021-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-04-15 | Eingeleitet | Needham | Buy |
| 2021-03-11 | Fortgesetzt | Goldman | Buy |
| 2021-01-15 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-01-07 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-09-22 | Eingeleitet | DA Davidson | Buy |
| 2020-07-27 | Eingeleitet | BofA Securities | Buy |
| 2020-07-27 | Eingeleitet | Credit Suisse | Neutral |
| 2020-07-27 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Accolade Inc Aktie (ACCD) Neueste Nachrichten
Accolade (NASDAQ:ACCD) Rating Lowered to Hold at Leerink Partnrs - MarketBeat
Transcarent to acquire health advocacy and primary care company Accolade for $621m - MSN
Stifel Nicolaus Reaffirms Hold Rating for Accolade (NASDAQ:ACCD) - MarketBeat
Estimate suggests Accolade may outperform with a potential 320% upside - Dataconomy
Accolade, with 500 employees in Montco, to be acquired in $621M deal - The Business Journals
Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Raymond James - MarketBeat
Accolade to be acquired by Transcarent for $7.03 per share in cash - Yahoo Finance
How Accolade stock pulled off a 105% jump - Dataconomy
Stifel downgrades Accolade stock as competing bids deemed unlikely - Investing.com
Stifel Downgrades Accolade Inc. (ACCD) to Hold - StreetInsider.com
Raymond James Downgrades Accolade Inc. (ACCD) to Market Perform - StreetInsider.com
Earnings Scheduled For January 9, 2025 - Benzinga
Accolade Gets a Do-Over With Transcarent’s $621M Acquisition - MedCity News
Seattle health care company to go private in $621 million acquisition deal - The Business Journals
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc.ACCD - Business Wire
Truist maintains Buy on Accolade stock, reiterates $7.50 target By Investing.com - Investing.com South Africa
Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
What Transcarent's $621M Acquisition of Accolade Means for Behavioral Health - Behavioral Health Business
Why Is Accolade Stock Trading Over 100% On Tuesday? - Benzinga
What's Going On With Accolade Stock Wednesday? - Benzinga
Truist maintains Buy on Accolade stock, reiterates $7.50 target - Investing.com India
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Leerink Partners - MarketBeat
Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade - Law360
Geode Capital Management Increases Stake in Accolade, Inc. – Market - HPBL
Accolade Inc. (ACCD): Q3 2025 Earnings Preview and Stock Outlook – Market - HPBL
Halper Sadeh LLC Investigates Accolade, Inc. Sale to Transcarent for Fairness to Shareholders - HPBL
Transcarent to acquire fellow health benefits navigator Accolade for $621M - Healthcare Dive
Accolade (ACCD) Stock Update: Analyst Ratings and Market Performance – Market - HPBL
Truist Securities Reiterates Buy Rating on Accolade Inc. (ACCD) - StreetInsider.com
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Accolade, Inc.ACCD - Longview News-Journal
Accolade (NASDAQ:ACCD) Shares Gap UpWhat's Next? - MarketBeat
Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade - GeekWire
Transcarent to acquire Accolade for $621 million creating benefits tech giant - STAT
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders - Business Wire
Accolade Acquired by Transcarent in Strategic Merger - TipRanks
Accolade stock soars on $621M Transcarent acquisition deal - Investing.com
Transcarent to acquire health benefits platform Accolade in $621M deal - Fierce healthcare
Accolade (ACCD) to Resume Trading at 9 am - StreetInsider.com
Transcarent To Acquire Accolade - GlobeNewswire
Transcarent To Acquire Accolade (ACCD) for $7.03 per share - StreetInsider.com
Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Exp - GuruFocus.com
Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Transcarent, Inc. agreed to acquire Accolade, Inc. from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others. - Marketscreener.com
Accolade’s chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Nigeria
AcCOLADE EVP general counsel sells shares worth $1,338 - Investing.com India
Accolade's chief accounting officer sells shares worth $1,785 - Investing.com
AcCOLADE EVP general counsel sells shares worth $1,338 By Investing.com - Investing.com Australia
Accolade's chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Australia
Newport News-based ivWatch receives accolades for life-saving technology - The Virginian-Pilot
Finanzdaten der Accolade Inc-Aktie (ACCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Accolade Inc-Aktie (ACCD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McHugh Colin | Chief Accounting Officer |
Jan 03 '25 |
Sale |
3.41 |
524 |
1,785 |
62,066 |
| Cavanaugh Robert N | President |
Jan 02 '25 |
Option Exercise |
0.00 |
1,569 |
0 |
214,864 |
| Cavanaugh Robert N | President |
Jan 03 '25 |
Sale |
3.41 |
553 |
1,884 |
214,311 |
| SINGH RAJEEV | Chief Executive Officer |
Jan 02 '25 |
Option Exercise |
0.00 |
3,786 |
0 |
819,637 |
| SINGH RAJEEV | Chief Executive Officer |
Jan 03 '25 |
Sale |
3.41 |
1,158 |
3,945 |
818,479 |
| Barnes Stephen H. | Chief Financial Officer |
Jan 02 '25 |
Option Exercise |
0.00 |
1,569 |
0 |
222,032 |
| Barnes Stephen H. | Chief Financial Officer |
Jan 03 '25 |
Sale |
3.41 |
535 |
1,823 |
221,497 |
| Eskew Richard | EVP General Counsel |
Jan 02 '25 |
Option Exercise |
0.00 |
1,146 |
0 |
63,653 |
| Eskew Richard | EVP General Counsel |
Jan 03 '25 |
Sale |
3.41 |
393 |
1,339 |
63,260 |
0.33%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):